[HTML][HTML] Efficacy and safety of bleselumab in kidney transplant recipients: A phase 2, randomized, open-label, noninferiority study
RC Harland, G Klintmalm, S Jensik, H Yang… - American Journal of …, 2020 - Elsevier
This study assessed the efficacy and safety of the anti-CD40 monoclonal antibody
bleselumab (ASKP1240) in de novo kidney transplant recipients over 36 months
posttransplant. Transplant recipients were randomized (1: 1: 1) to standard of care (SoC: 0.1
mg/kg per day immediate-release tacrolimus [IR-TAC]; target minimum blood concentration
[C trough] 4-11 ng/mL plus 1 g mycophenolate mofetil [MMF] twice daily) or bleselumab (200
mg on days 0/7/14/28/42/56/70/90, and monthly thereafter) plus either MMF or IR-TAC (0.1 …
bleselumab (ASKP1240) in de novo kidney transplant recipients over 36 months
posttransplant. Transplant recipients were randomized (1: 1: 1) to standard of care (SoC: 0.1
mg/kg per day immediate-release tacrolimus [IR-TAC]; target minimum blood concentration
[C trough] 4-11 ng/mL plus 1 g mycophenolate mofetil [MMF] twice daily) or bleselumab (200
mg on days 0/7/14/28/42/56/70/90, and monthly thereafter) plus either MMF or IR-TAC (0.1 …
